Healthcare Providers and Services
Company Overview of Boston Heart Diagnostics Corporation
Boston Heart Diagnostics Corporation provides heart diagnostic services in the United States. The company offers personalized diagnostics and reports, and customized nutrition and lifestyle programs for healthcare providers and their patients. It offers Boston Heart HDL Map, a test that quantifies the amount of apoA-I in the five most significant subpopulations, resulting in an understanding of a patient’s cardiovascular disease (CVD) risk; Boston Heart Cholesterol Balance Test, a test that directly measures the production and absorption markers for circulating plasma cholesterol; Boston Heart Statin Induced Myopathy (SLCO1B1) Genotype test that identifies those patients who are at higher ri...
175 Crossing Boulevard
Framingham, MA 01702
Founded in 2007
Key Executives for Boston Heart Diagnostics Corporation
Co-Founder, Chief Medical Officer, Director and Member of Scientific Advisory Board
Co-Founder, Chief Scientific Officer and Member of Scientific Advisory Board
Senior Vice President of Operations
Compensation as of Fiscal Year 2016.
Boston Heart Diagnostics Corporation Key Developments
Boston Heart Announces the Launch of Life Plan 2.0
Jan 20 16
Boston Heart announced the launch of Life Plan 2.0, the next generation of its scientifically-designed nutrition and lifestyle plan that helps patients achieve their weight management goal and their overall heart health. This easy to understand plan provides patients at risk for cardiovascular disease with a strategy to help them take control of their heart health. Grounded in science, Life Plan 2.0 takes Boston Heart’s Nutrition and Lifestyle Program to the next level by providing a truly individualized plan for each unique patient. The plan features customized weight and fitness goals and specific recommendations to improve biomarker test results and to reduce heart disease risk.
Boston Heart Diagnostics Introduces StatinSmart
Nov 19 15
Boston Heart Diagnostics announced the launch of StatinSmart, the first and only at-home saliva laboratory developed test that analyzes the SLCO1B1 (Solute Carrier Organic Anion Transporter 1B1) gene for a variant known to increase an individual’s risk for developing statin induced myopathy - the onset of muscle aches, spasms and pain associated with statin therapy. StatinSmart helps patients understand how their bodies will process a statin and encourages them to discuss with their healthcare provider the type of statin that is best suited to their genotype. With this information, patients can work with their healthcare provider to personalize a plan to lower cholesterol without unnecessary side effects.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries